Verastem (VSTM) News Today $4.00 +0.07 (+1.78%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Verastem Inc. Reports Increased Operating Expenses and Net LossNovember 22 at 5:29 AM | markets.businessinsider.comVerastem (NASDAQ:VSTM) Cut to "Sell" at StockNews.comNovember 22 at 1:59 AM | americanbankingnews.comB. Riley Forecasts Verastem's FY2024 Earnings (NASDAQ:VSTM)Verastem, Inc. (NASDAQ:VSTM - Free Report) - Stock analysts at B. Riley increased their FY2024 earnings per share estimates for shares of Verastem in a report issued on Monday, November 18th. B. Riley analyst K. Patel now anticipates that the biopharmaceutical company will post earnings per shareNovember 21 at 6:32 AM | marketbeat.comAnalysts Set Verastem, Inc. (NASDAQ:VSTM) Price Target at $14.57November 20, 2024 | americanbankingnews.comOrbiMed Advisors LLC's Strategic Acquisition of Verastem Inc SharesNovember 15, 2024 | gurufocus.comVerastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from AnalystsShares of Verastem, Inc. (NASDAQ:VSTM - Get Free Report) have earned an average recommendation of "Buy" from the eight analysts that are covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average twelve-month price target among broNovember 15, 2024 | marketbeat.comVerastem price target lowered to $14 from $20 at Alliance Global PartnersNovember 7, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Verastem (VSTM)November 7, 2024 | markets.businessinsider.comVerastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business UpdatesNovember 6, 2024 | businesswire.comStrategic Advancements and Market Opportunities Propel Verastem’s Buy RatingNovember 5, 2024 | markets.businessinsider.comOptimistic Buy Rating: Strong Phase 2 Results and Regulatory Progress for Verastem’s Avutometinib and DefactinibOctober 22, 2024 | markets.businessinsider.comVerastem (NASDAQ:VSTM) Stock Quotes, Forecast and News SummaryOctober 19, 2024 | benzinga.comVerastem’s Promising Advancements in LGSOC Treatment Drive Buy Rating with $7 TargetOctober 19, 2024 | markets.businessinsider.comVerastem Stock: Buy Rating Amid Market Overreaction and Promising Commercial PotentialOctober 18, 2024 | markets.businessinsider.comRoyal Bank of Canada Reaffirms "Outperform" Rating for Verastem (NASDAQ:VSTM)Royal Bank of Canada reaffirmed an "outperform" rating and issued a $13.00 target price on shares of Verastem in a research report on Friday.October 18, 2024 | marketbeat.comVerastem (NASDAQ:VSTM) Given "Overweight" Rating at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of Verastem in a research note on Friday.October 18, 2024 | marketbeat.comVerastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual MeetingOctober 17, 2024 | businesswire.comVerastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual MeetingOctober 9, 2024 | businesswire.comVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 7, 2024 | businesswire.comGuggenheim Initiates Coverage of Verastem (VSTM) with Buy RecommendationOctober 1, 2024 | msn.comNantahala Capital Management LLC Purchases Shares of 400,000 Verastem, Inc. (NASDAQ:VSTM)Nantahala Capital Management LLC acquired a new position in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 400,000 shares of the biopharmaceutical company's stockOctober 1, 2024 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Given Average Recommendation of "Buy" by AnalystsVerastem, Inc. (NASDAQ:VSTM - Get Free Report) has earned a consensus rating of "Buy" from the six research firms that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price objective among analystsSeptember 26, 2024 | marketbeat.comVerastem Oncology to Present at the 2024 Cantor Global Healthcare ConferenceSeptember 10, 2024 | businesswire.comVerastem's Path To FDA Approval: High-Risk, High-Reward Oncology OpportunitySeptember 6, 2024 | seekingalpha.comVerastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024September 3, 2024 | financialpost.comVerastem, Inc. (NASDAQ:VSTM) Receives Average Rating of "Buy" from AnalystsShares of Verastem, Inc. (NASDAQ:VSTM - Get Free Report) have earned an average recommendation of "Buy" from the six analysts that are currently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price objectSeptember 1, 2024 | marketbeat.comOutperform Rating and $7 Target for Verastem Amidst LGSOC Treatment Potential and Stock Valuation OpportunityAugust 22, 2024 | markets.businessinsider.comVerastem, Inc. (NASDAQ:VSTM) Short Interest Down 18.9% in JulyVerastem, Inc. (NASDAQ:VSTM - Get Free Report) was the target of a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 1,840,000 shares, a drop of 18.9% from the July 15th total of 2,270,000 shares. Currently, 5.9% of the company's shares are sold short. Based on an average daily trading volume, of 1,020,000 shares, the short-interest ratio is presently 1.8 days.August 15, 2024 | marketbeat.comVerastem (NASDAQ:VSTM) Given New $15.00 Price Target at Truist FinancialTruist Financial decreased their price objective on shares of Verastem from $18.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday.August 13, 2024 | marketbeat.comVerastem (NASDAQ:VSTM) Raised to "Hold" at StockNews.comStockNews.com upgraded Verastem from a "sell" rating to a "hold" rating in a report on Monday.August 12, 2024 | marketbeat.comHC Wainwright Cuts Verastem (NASDAQ:VSTM) Price Target to $7.00HC Wainwright lowered their price target on Verastem from $17.50 to $7.00 and set a "buy" rating on the stock in a research report on Monday.August 12, 2024 | marketbeat.comBuy Rating Affirmed for Verastem: Financial Stability and Promising Drug Pipeline Fuel OptimismAugust 12, 2024 | markets.businessinsider.comVerastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business UpdatesAugust 9, 2024 | finance.yahoo.comBuy Rating Justified by Verastem’s Promising LGSOC Drug Prospects and Strong Market PositionAugust 9, 2024 | markets.businessinsider.comRoyal Bank of Canada Trims Verastem (NASDAQ:VSTM) Target Price to $13.00Royal Bank of Canada decreased their price target on Verastem from $16.00 to $13.00 and set an "outperform" rating for the company in a research note on Friday.August 9, 2024 | marketbeat.comVSTM Stock Earnings: Verastem Beats EPS, Beats Revenue for Q2 2024August 9, 2024 | investorplace.comVSTM Aug 2024 2.000 callAugust 4, 2024 | ca.finance.yahoo.comVerastem (NASDAQ:VSTM) Lowered to Sell at StockNews.comStockNews.com downgraded Verastem from a "hold" rating to a "sell" rating in a report on Thursday.August 1, 2024 | marketbeat.comVerastem Oncology receives FDA Orphan Drug DesignationJuly 31, 2024 | investing.comVerastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic CancerJuly 30, 2024 | finance.yahoo.comVerastem, Inc. Expected to Post Q3 2024 Earnings of ($0.79) Per Share (NASDAQ:VSTM)Verastem, Inc. (NASDAQ:VSTM - Free Report) - Research analysts at B. Riley upped their Q3 2024 earnings estimates for Verastem in a report issued on Wednesday, July 24th. B. Riley analyst K. Patel now expects that the biopharmaceutical company will post earnings of ($0.79) per share for the quartJuly 26, 2024 | marketbeat.comShort Interest in Verastem, Inc. (NASDAQ:VSTM) Grows By 77.3%Verastem, Inc. (NASDAQ:VSTM - Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 2,270,000 shares, a growth of 77.3% from the June 30th total of 1,280,000 shares. Approximately 11.2% of the company's stock are short sold. Based on an average daily volume of 906,700 shares, the days-to-cover ratio is currently 2.5 days.July 26, 2024 | marketbeat.comVerastem (NASDAQ:VSTM) Price Target Cut to $7.00B. Riley lowered their price objective on shares of Verastem from $21.00 to $7.00 and set a "buy" rating for the company in a research report on Wednesday.July 24, 2024 | marketbeat.comVerastem Oncology slumps 26%, prices $55M offeringJuly 24, 2024 | msn.comVerastem Oncology Announces Pricing Of $55.0 Mln Offering Of Common Stock, WarrantsJuly 24, 2024 | markets.businessinsider.comVerastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded WarrantsJuly 24, 2024 | finance.yahoo.comVerastem Shares Drop 25% After Public Offering NewsJuly 23, 2024 | marketwatch.comVerastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded WarrantsJuly 23, 2024 | businesswire.comInflaRx NV (IF0.DU)July 20, 2024 | finance.yahoo.comVerastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Buy" from BrokeragesVerastem, Inc. (NASDAQ:VSTM - Get Free Report) has earned an average recommendation of "Buy" from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year price target among analJuly 13, 2024 | marketbeat.com Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Bill Gates’s Next Big AI Bet: Stargate (Ad)In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then. I believe we are about to do it again with this new AI project called Stargate VSTM Media Mentions By Week VSTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VSTM News Sentiment▼0.670.50▲Average Medical News Sentiment VSTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VSTM Articles This Week▼73▲VSTM Articles Average Week Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MEI Pharma News Ironwood Pharmaceuticals News Emergent BioSolutions News Rigel Pharmaceuticals News Sangamo Therapeutics News XOMA News Codexis News Vanda Pharmaceuticals News Lexicon Pharmaceuticals News Achieve Life Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VSTM) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
